从7月以来，全国各地陆续进入烧烤模式，与空调、冷饮、WIFI关注度同样飙升的还有各类具有清热祛 暑、化湿和中、益气生津等功效的袪暑药品。北京同仁堂科技发展股份有限公司（以下简称"同仁堂科 技公司"）调整产能，提升效率，供应仁丹、藿香正气水等袪暑产品及时充分供应。 仁丹、藿香正气水等具有清热解暑、提神醒脑、祛暑化湿、解表和中等功效，是家庭药箱中重要的袪暑 产品。针对市场要货需求，同仁堂科技公司提前安排生产计划，增加暑期用药人员排班，同时在袪暑品 种的原材料采购与鉴别、前处理炮制、制药与质检环节开通"绿色通道"。 赶紧了解一下吧 在生产过程中，企业不断提升现代化、智能化设备使用比例，例如在仁丹生产中，引入离心式包衣造粒 机，对各生产工序进行标准化流程管理。据了解，离心式包衣造粒机利用离心力使物料有序运动，配合 精准雾化喷涂与自动化控制，只需预先设定好相关参数，机器便能自动完成后续操作。 为了避免藿香正气水在服用时的刺激气味，企业引入的藿香祛暑软胶囊生产线开足马力，研配间的真空 乳化搅拌持续运转，化胶罐内的明胶和甘油在上下翻涌，压丸工序的滚模式软胶囊机稳定运行，内外包 装线紧密衔接，各个工序如齿轮般紧密咬合。目前， ...

Core Insights - The company is actively promoting its seasonal health products during summer events in Beijing, showcasing items like loquat syrup and various herbal products [1][4] - The company emphasizes the integration of traditional Chinese medicine with modern health concepts, particularly through its aromatic products [2][11] Group 1: Product Offerings - The company has launched over 100 aromatic products, including incense, essential oils, and cultural items, based on the traditional Chinese philosophy of "medicinal fragrance" [2][15] - Seasonal products such as loquat syrup, which contains 30% fresh loquat pulp, and various flavors of ready-to-eat ejiao cake have attracted significant consumer interest [4][9] Group 2: Community Engagement - The company participated in the "Health China Tour" event, providing health lectures and showcasing summer health products to local residents [6][9] - The company is involved in community welfare activities, aiming to deliver health benefits to citizens through various outreach programs [4][9] Group 3: Cultural Promotion - At the "Asian Infrastructure Investment Bank Annual Meeting," the company demonstrated traditional ejiao-making techniques, highlighting the cultural heritage of Chinese medicine [11][13] - The company’s aromatic products have gained popularity among international guests, showcasing the blend of traditional craftsmanship and modern aesthetics [15]

Core Viewpoint - Beijing Tongrentang Technology Development Co., Ltd. is actively participating in cultural tourism events to enhance consumer experiences through its creative fragrance products, emphasizing the integration of traditional Chinese medicine with modern lifestyle aesthetics [1][8]. Product Offerings - The company’s creative fragrance products are based on the "medicinal fragrance origin" concept, combining traditional pharmaceutical techniques with intangible cultural heritage of incense-making, featuring over 100 products across seven series, including incense, bracelets, pendants, sachets, and essential oils [3][8]. - Notable products include the "Anping Fragrance" and "Ankang Fragrance" sachets, which are designed to offer blessings for health during the Dragon Boat Festival, and seasonal incense products aimed at providing natural protection against summer ailments [10]. Market Engagement - The company’s booth at the event attracted numerous visitors, showcasing a variety of creatively designed fragrance products that appealed to different age groups, particularly younger consumers [3][10]. - The innovative liquid fragrance products, such as "Xinyue" and "Wuyu," have gained popularity for their modern interpretations of traditional scents, facilitating a transition from time anxiety to a state of tranquility [8]. Cultural Integration - The company’s products reflect a blend of traditional Chinese medicine and contemporary lifestyle, aiming to make traditional culture more accessible and relevant to modern consumers [8][10]. - The "Four Seasons Combined Fragrance" incense gift box is designed based on traditional Chinese medicine principles, aligning with seasonal changes and promoting a connection to nature [10].

智通财经APP讯，同仁堂科技(01666)发布公告，于2025年6月4日，北京同仁堂科技发展股份有限公司 (本公司，及其附属公司，本集团)董事会接到邸淑兵先生(邸先生)、陈加富先生(陈先生)及冯智梅女士 (冯女士)各自的辞任函，告知董事会邸先生由于工作变动原因申请辞任本公司董事、董事长、董事会辖 下的提名委员会(提名委员会)主席及战略与规划委员会(战略与规划委员会)主席及香港联合交易所(香港 联交所)有限公司证券上市规则第3.05条项下的本公司授权代表(授权代表);陈先生由于工作变动原因申 请辞任本公司董事、战略与规划委员会委员及本公司总经理(总经理);及冯女士由于工作变动原因申请辞 任本公司董事及本公司副总经理。 上述邸先生辞任本公司董事长、提名委员会主席及战略与规划委员会主席及授权代表，陈先生辞任总经 理及冯女士辞任本公司副总经理均已自2025年6月4日起生效。 董事会于2025年6月4日决议： (i)非执行董事张毅先生已调任为执行董事，其任期自2025年6月4日起至 本届董事会任期结束终止，并在其任期届满时可以连选连任。董事会建议提请股东大会批准张毅先生担 任本公司执行董事的薪酬为零，张毅先生将依据其在 ...

Core Viewpoint - The 17th Ditan Traditional Chinese Medicine Health Culture Festival was successfully held in Beijing, showcasing the integration of traditional culture and health through various TCM products and practices [1]. Company Overview - Tongrentang Technology Development Co., Ltd. showcased a wide range of health products, emphasizing its strength in the health industry and innovative capabilities [3][5]. - The company has developed a product matrix in the health sector, including six major categories: health foods, health drinks, deer products, cosmetics, fragrance products, and disinfection products [3]. Product Highlights - The festival featured dozens of representative products from the "big health" matrix, demonstrating the company's rich heritage in TCM culture and product development [5]. - The traditional production technique of Ejiao cake was demonstrated live, highlighting the craftsmanship and time-intensive process involved [7]. - The company has developed nearly 200 fragrance products based on classic TCM formulas, integrating traditional medicine with modern fragrance techniques [9][11]. - The cosmetics division focuses on the research and application of traditional plants, with products like ginseng vitamin E lotion gaining popularity among consumers [13]. Cultural Impact - The festival allowed the public to deeply experience the charm of TCM culture and health services, promoting the benefits of TCM to a wider audience [15].

Group 1 - The "She Health - Meituan Women's Health Public Welfare Program" was officially launched in Shanghai, focusing on creating a health management system for over 30 working women through a collaboration between government, enterprises, and medical institutions [1][3] - Beijing Tongrentang, a representative brand of traditional Chinese medicine, emphasizes the importance of liver health for women and integrates the concept of "preventive treatment" into health management, addressing modern women's health needs [3][5] - The program aims to enhance health awareness from individual to societal levels, promoting the core idea of "soothing the liver and relieving stress" [3][5] Group 2 - The collaboration with Meituan to release the "Women's Health White Paper" is a significant initiative in response to the "Healthy China" strategy, aiming to provide more precise health services through data insights and resource integration [5] - The event featured a health consultation area where experienced traditional Chinese medicine practitioners offered personalized health solutions for issues like "liver stagnation and qi deficiency" [7] - Beijing Tongrentang's mission is to make traditional Chinese medicine accessible to everyone, ensuring that every working woman can thrive with a balanced approach to health [7]

Group 1 - The second "Jiawei Xiaoyao Wan - Pharmacy Speaker" event, sponsored by Tongrentang Technology Development Co., Ltd., will start on May 8 and aims to enhance the professional skills of pharmacy staff over a five-month competition [1][3] - The event focuses on empowering pharmacy talent development and improving service quality, aligning with the growing consumer health demands in the domestic market [3][5] - The competition will include various stages such as online preliminaries, online rematch, semifinals, and finals, with opportunities for participants to win cash prizes and gifts [7] Group 2 - The event emphasizes "professional enhancement" and "customer attraction," using Tongrentang's flagship product, Jiawei Xiaoyao Wan, to help pharmacy staff understand product characteristics and market trends [5][3] - Participants can win up to 5,000 yuan in cash rewards and additional prizes for outstanding performance, which can also help drive traffic to their stores [7][5] - The competition format includes PK mode, group challenges, practical exercises, and professional skill contests to comprehensively improve pharmacy operations [5][7]

Core Insights - In Q1 2025, Tongrentang Technology Company focused on market demand, enhancing product variety and channel development to stimulate marketing momentum [1] Group 1: Product Strategy - The company emphasized "focusing" on major products, directing promotional resources towards key varieties such as Yao Medicine 300 Years, Ejiao, and children's medicine, creating a clear product structure [1] - Core products like Xihuang Pill, Jingzhi Niuhuang Jiedu Pian, and Liuwuwei Dihuang Wan series have optimized pricing systems and operational strategies, achieving coverage in over 30 provinces [9] Group 2: Marketing Initiatives - The "Flag Planting Action" marketing campaign covered 10 key provinces, conducting 206 events and nearly 1500 terminal promotion activities, successfully enhancing product shelf presence and awareness [9] - The company targeted younger audiences with innovative marketing strategies, such as the "Beijing Tongrentang Super Good Pill" campaign during the JD Super Brand Day, appealing to their health-conscious yet skeptical mindset [11] Group 3: Community Engagement - The company engaged in community education about product knowledge, leveraging events like the Winter Olympics to promote health trends, particularly in Harbin [11][14] - Creative marketing slogans and campaigns, such as the AI-themed short films, resonated with younger demographics, making products like Jingzhi Niuhuang Jiedu Pian and Ejiao popular during the spring health season [12][14]

Financial Performance - The company reported a revenue increase of 12% year-over-year, reaching $1.2 billion for the fiscal year 2024[6]. - For the year ended December 31, 2024, the Group's revenue amounted to RMB 7,259,644,000, representing an increase of 7.18% from RMB 6,773,463,000 for the corresponding period of last year[27]. - The net profit for the year was RMB 886,933,000, a decrease of 10.62% from RMB 992,313,000 in the previous year[27]. - Profit attributable to owners of the Company was RMB 521,795,000, down 11.59% from RMB 590,188,000 in 2023[27]. - Earnings per share decreased to RMB 0.41 from RMB 0.46 in 2023[27]. - The gross margin improved to 55%, up from 52% in the previous year, due to cost optimization strategies[6]. - The gross margin for 2024 was 39.64%, down from 42.04% in 2023[22]. - The gross margin for the year ended December 31, 2024, was 39.64%, down from 42.04% in 2023, while the net profit margin decreased to 12.22% from 14.65%[75]. - The Group's total revenue for the year ended December 31, 2024, was RMB 7,259,644,000, an increase from RMB 6,773,463,000 in 2023, representing a growth of approximately 7.2%[107]. User Growth and Market Expansion - User data showed a growth in active users by 15%, totaling 5 million users by the end of 2024[6]. - Market expansion efforts led to a 25% increase in sales in the Southeast Asia region, now accounting for 30% of total sales[6]. - A new partnership with a leading e-commerce platform is projected to boost online sales by 30% in the upcoming year[6]. Product Development and R&D - New product launches contributed to 20% of total revenue, with three major products introduced in Q4 2024[6]. - The company invested $50 million in R&D for new technologies, focusing on enhancing product efficacy and user experience[6]. - The Group's innovative drug Qishen Granules successfully obtained the Notice of Approval for Clinical Trial, enhancing its research and development capabilities[52]. - Research and development expenses for the year ended December 31, 2024, were RMB 84,823,000, accounting for 1.17% of revenue, down from 1.74% in 2023[76]. Strategic Initiatives - The Group adjusted its marketing strategies to enhance consumer experience and broaden sales channels in response to market challenges[30]. - The Group will continue to optimize its strategic management system and marketing reforms as part of the "14th Five-Year Plan" initiatives[42]. - The Group's marketing strategies include the "Glow Campaign" and "Flag-planting Campaign" to enhance market penetration and consumer engagement[46]. - The Group aims to optimize production processes and improve supply security systems to support growth during the 15th Five-Year Plan[97][100]. Financial Position and Liquidity - The current ratio decreased to 3.81 from 4.49 in 2023, indicating a decline in liquidity[22]. - Total assets increased to RMB 14,408,591,000 from RMB 13,507,742,000 in 2023[22]. - The debt to asset ratio rose to 29.45% from 28.55% in 2023, reflecting a slight increase in leverage[22]. - The liquidity ratio as of December 31, 2024, was 3.81, down from 4.49 in 2023, indicating a decrease in financial resources[64]. - Cash and cash equivalents increased to RMB 412,948,800 as of December 31, 2024, from RMB 274,645,800 in 2023[66]. Challenges and Risks - The Group faced significant increases in raw material costs due to supply chain constraints and rising market demand, impacting production costs[45]. - The Group faces major risks including policy risks and operational risks, which may impact business operations and financial performance[146]. - Increasing regulatory standards in pharmaceuticals impose higher requirements on safety and environmental management, leading to potential cost increases[147]. - The Group's production of Chinese patent medicines involves complex processes and strict quality control, with potential risks of sporadic issues affecting reputation and finances[149]. Shareholder Information - As of December 31, 2024, substantial shareholders held a total of 617,129,000 shares, representing 93.46% of the issued shares[141]. - The largest customer, Tong Ren Tang Holdings and its subsidiaries, contributed RMB 2,257,367,000, representing 31.09% of total revenue, up from 23.61% in 2023[119]. - The Group's purchases from the five largest suppliers accounted for 31.24% of total purchases, with the largest supplier contributing 10.47%[119]. Legal and Compliance - The Group is committed to compliance with various laws and regulations, including the Company Law and Good Manufacturing Practice, to mitigate legal risks[156]. - The Group has implemented a strategic deployment for legal compliance and risk management, enhancing its governance and integrity systems[157]. - There were no significant legal risk events or non-compliance issues reported during the year[158].

Financial Performance - For the fiscal year ending December 31, 2024, the company's revenue was RMB 7,259.644 million, an increase of 7.18% from RMB 6,773.463 million in the previous year[4] - The net profit for the same period was RMB 886.933 million, a decrease of 10.62% compared to RMB 992.313 million in the previous year[4] - Earnings attributable to the company's owners were RMB 521.795 million, down 11.59% from RMB 590.188 million in the previous year[4] - The basic and diluted earnings per share were RMB 0.41, compared to RMB 0.46 in the previous year[4] - The total comprehensive income for the year was RMB 953.635 million, compared to RMB 1,041.687 million in the previous year[13] - Financial income for 2024 was RMB 76,874, down 19.4% from RMB 95,351 in 2023[34] - The net financial income decreased significantly to RMB 8,577 in 2024 from RMB 46,049 in 2023[34] - The total income tax expense for 2024 is RMB 174,278,000, compared to RMB 170,142,000 in 2023, reflecting an increase of approximately 0.8%[41] - The effective tax rate for 2024 is 21.2%, up from 20.0% in 2023, indicating a rise in the tax burden on pre-tax profits[43] - Basic earnings per share for 2024 is RMB 0.41, down from RMB 0.46 in 2023, representing a decrease of approximately 10.9%[51] - The profit attributable to the owners of the company for 2024 is RMB 521,795,000, compared to RMB 590,188,000 in 2023, showing a decline of about 11.6%[51] Assets and Liabilities - Total assets increased to RMB 14,408,591 thousand in 2024, up from RMB 13,507,742 thousand in 2023, representing a growth of 6.6%[15] - Current assets rose to RMB 10,833,476 thousand in 2024, compared to RMB 10,058,898 thousand in 2023, marking an increase of 7.7%[15] - Total equity rose to RMB 10,165,079 thousand in 2024, up from RMB 9,651,885 thousand in 2023, which is an increase of 5.3%[16] - Non-current liabilities decreased to RMB 1,402,041 thousand in 2024 from RMB 1,616,972 thousand in 2023, a decline of 13.2%[16] - Current liabilities increased to RMB 2,841,471 thousand in 2024, compared to RMB 2,238,885 thousand in 2023, representing an increase of 27%[16] - The company's reserves increased to RMB 5,925,413 thousand in 2024, up from RMB 5,608,633 thousand in 2023, reflecting a growth of 5.6%[16] - The total assets of the company as of December 31, 2024, amount to RMB 14,408,591,000, while total liabilities are RMB 4,243,512,000[55] Inventory and Receivables - Inventory increased significantly to RMB 5,165,995 thousand in 2024, up from RMB 4,744,433 thousand in 2023, reflecting a growth of 8.9%[15] - The company reported a significant increase in accounts receivable to RMB 1,103,565 thousand in 2024, compared to RMB 888,333 thousand in 2023, which is an increase of 24.2%[15] - Accounts receivable increased to RMB 887,968,000 in 2024 from RMB 721,230,000 in 2023, with third-party receivables rising to RMB 612,158,000[63] - The net value of accounts receivable and notes was RMB 1,103,565,000 in 2024, compared to RMB 888,333,000 in 2023[63] Strategic Initiatives - The company plans to enhance its marketing strategies and optimize its strategic management system to improve market influence and share[8] - The company is focusing on technological innovation and industry upgrades to drive modernization in the traditional Chinese medicine sector[8] - The company aims to strengthen its product offerings and expand sales channels to enhance competitiveness in a challenging market environment[6] - The company is focusing on the development of classic formulas, including Linggui Zhugan Decoction and Shaoyao Gancao Decoction[89] - The company is conducting clinical research on existing products to enhance their market competitiveness and clinical acceptance[89] Research and Development - Research and development expenses for 2024 were RMB 84,823, a decrease of 27.8% from RMB 117,556 in 2023[37] - Research and development expenditure (excluding employee benefits, depreciation, and amortization) was RMB 84.8 million, accounting for 1.17% of revenue[104] Market Performance - In 2024, the sales revenue of traditional Chinese medicine products reached RMB 5,897,495, an increase of 7.3% from RMB 5,495,458 in 2023[28] - The sales of the Liuwei Dihuang Wan series increased by 10.71%, while the Shengmai Drink series saw a growth of 14.85% year-on-year[89] - Tong Ren Tang Guo Yao achieved a sales revenue of RMB 1,473.4 million in 2024, representing a year-on-year growth of 7.04%[91] - The six subsidiaries focused on traditional Chinese medicine raw materials achieved a combined sales revenue of RMB 482.9 million, with a year-on-year growth of 13.76%[92] Corporate Governance - The group is committed to adhering to corporate governance standards as per the Hong Kong Stock Exchange listing rules, ensuring a robust governance framework[117] - Ernst & Young has been appointed as the auditor for the fiscal year ending December 31, 2024, and their work aligns with the group's financial performance announcements[123] Challenges and Outlook - The company faced significant challenges due to rising raw material costs, impacting production costs and supply chain management[86] - The group aims to optimize production processes and enhance production efficiency while controlling costs and inventory levels, focusing on "maintaining output value, controlling costs, adjusting structure, and reducing inventory"[114] - The group anticipates a prosperous and internationally influential traditional Chinese medicine industry, supported by national health strategies and policies[114]